GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (OSTO:ONCOZ) » Definitions » Debt-to-Revenue

OncoZenge AB (OSTO:ONCOZ) Debt-to-Revenue : N/A (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

OncoZenge AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr0.00 Mil. OncoZenge AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr0.00 Mil. OncoZenge AB's annualized Revenue for the quarter that ended in Dec. 2024 was kr0.00 Mil.


OncoZenge AB Debt-to-Revenue Historical Data

The historical data trend for OncoZenge AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoZenge AB Debt-to-Revenue Chart

OncoZenge AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
N/A N/A N/A N/A N/A

OncoZenge AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of OncoZenge AB's Debt-to-Revenue

For the Biotechnology subindustry, OncoZenge AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoZenge AB's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoZenge AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where OncoZenge AB's Debt-to-Revenue falls into.



OncoZenge AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

OncoZenge AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

OncoZenge AB's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


OncoZenge AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of OncoZenge AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoZenge AB Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 34, Bromma, SWE, 167 51
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

OncoZenge AB Headlines

No Headlines